BrightSpring Health Analyst Price Targets

Wall Street analyst price targets and consensus rating for BrightSpring Health (BTSG).

Price Target Range — 11 Quarters

Analyst Consensus — 19 Analysts

1S.Buy

17Buy

1Hold

Consensus RatingBuy# Analysts19Avg. Consensus PT$54Upside to Avg. PT-8.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 13, 2026	BTIG	David Larsen	Maintained	Buy	$90
Aug 3, 2026	BTIG	David Larsen	Maintained	Buy	$90
Jul 14, 2026	Morgan Stanley	Erin Wright	PT Raise	Overweight	$71→$80
Jul 14, 2026	Keybanc	Matthew Gillmor	PT Raise	Overweight	$60→$80
Jul 13, 2026	Wells Fargo	Stephen Baxter	PT Raise	Overweight	$61→$78
Jul 13, 2026	Guggenheim	Jason Cassorla	Initiate	Buy	$81
Jul 10, 2026	Raymond James	Parker Snure	Initiate	Outperform	$80
Jul 8, 2026	UBS	A.J. Rice	PT Raise	Buy	$63→$85
Jul 2, 2026	B of A Securities	Kevin Fischbeck	PT Raise	Buy	$66→$77
Jun 22, 2026	BTIG	David Larsen	PT Raise	Buy	$65→$90
Jun 18, 2026	TD Cowen	Charles Rhyee	PT Raise	Buy	$65→$81
Jun 8, 2026	Goldman Sachs	Scott Fidel	Initiate	Buy	$71
Jun 2, 2026	Morgan Stanley	Erin Wright	PT Raise	Overweight	$62→$71
May 6, 2026	Morgan Stanley	Erin Wright	PT Raise	Overweight	$48→$62
May 5, 2026	Mizuho	Ann Hynes	PT Raise	Outperform	$52→$61
May 4, 2026	Wells Fargo	Stephen Baxter	PT Raise	Overweight	$50→$61
May 4, 2026	TD Cowen	Charles Rhyee	PT Raise	Buy	$60→$65
May 4, 2026	Keybanc	Matthew Gillmor	PT Raise	Overweight	$55→$60
May 4, 2026	Stephens & Co.	Raj Kumar	PT Raise	Overweight	$53→$64
May 4, 2026	BMO Capital	Sean Dodge	PT Raise	Outperform	$52→$60

Analyst Ratings News

PRO
BTIG Reiterates Buy on BrightSpring Health, Maintains $90 Price Target

BTIG analyst David Larsen reiterates BrightSpring Health (NASDAQ:BTSG) with a Buy and maintains $90 price target.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on BrightSpring Health, Maintains $90 Price Target

BTIG analyst David Larsen reiterates BrightSpring Health (NASDAQ:BTSG) with a Buy and maintains $90 price target.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on BrightSpring Health, Raises Price Target to $80

Morgan Stanley analyst Erin Wright maintains BrightSpring Health (NASDAQ:BTSG) with a Overweight and raises the price target from $71 to $80.

Benzinga Newsdesk

PRO
Keybanc Maintains Overweight on BrightSpring Health, Raises Price Target to $80

Keybanc analyst Matthew Gillmor maintains BrightSpring Health (NASDAQ:BTSG) with a Overweight and raises the price target from $60 to $80.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on BrightSpring Health, Raises Price Target to $78

Wells Fargo analyst Stephen Baxter maintains BrightSpring Health (NASDAQ:BTSG) with a Overweight and raises the price target from $61 to $78.

Benzinga Newsdesk

PRO
Guggenheim Initiates Coverage On BrightSpring Health with Buy Rating, Announces Price Target of $81

Guggenheim analyst Jason Cassorla initiates coverage on BrightSpring Health (NASDAQ:BTSG) with a Buy rating and announces Price Target of $81.

Benzinga Newsdesk

BrightSpring Health Services Inc

뉴스

파트너 / 기고자

벤징가 글로벌

BrightSpring Health Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
BTIG Reiterates Buy on BrightSpring Health, Maintains $90 Price Target

PRO
BTIG Reiterates Buy on BrightSpring Health, Maintains $90 Price Target

PRO
Morgan Stanley Maintains Overweight on BrightSpring Health, Raises Price Target to $80

PRO
Keybanc Maintains Overweight on BrightSpring Health, Raises Price Target to $80

PRO
Wells Fargo Maintains Overweight on BrightSpring Health, Raises Price Target to $78

PRO
Guggenheim Initiates Coverage On BrightSpring Health with Buy Rating, Announces Price Target of $81

People Also Watch

People Also Watch

BrightSpring Health Services Inc

뉴스

파트너 / 기고자

벤징가 글로벌

BrightSpring Health Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBTIG Reiterates Buy on BrightSpring Health, Maintains $90 Price Target

PROBTIG Reiterates Buy on BrightSpring Health, Maintains $90 Price Target

PROMorgan Stanley Maintains Overweight on BrightSpring Health, Raises Price Target to $80

PROKeybanc Maintains Overweight on BrightSpring Health, Raises Price Target to $80

PROWells Fargo Maintains Overweight on BrightSpring Health, Raises Price Target to $78

PROGuggenheim Initiates Coverage On BrightSpring Health with Buy Rating, Announces Price Target of $81

People Also Watch

People Also Watch

PRO
BTIG Reiterates Buy on BrightSpring Health, Maintains $90 Price Target

PRO
BTIG Reiterates Buy on BrightSpring Health, Maintains $90 Price Target

PRO
Morgan Stanley Maintains Overweight on BrightSpring Health, Raises Price Target to $80

PRO
Keybanc Maintains Overweight on BrightSpring Health, Raises Price Target to $80

PRO
Wells Fargo Maintains Overweight on BrightSpring Health, Raises Price Target to $78

PRO
Guggenheim Initiates Coverage On BrightSpring Health with Buy Rating, Announces Price Target of $81